Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $8.24 Analyst target: $25.50 Upside: 209.47%
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for autoinflammatory diseases that involve complement and leukotriene pathways. The company is headquartered in London, the United Kingdom.
See the full interactive analysis & chart →Informational only — not investment advice.